关于公司
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
US
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论